Imaging the PCP site of the NMDA ion channel

Nuclear Medicine and Biology

Volumn 30, Issue 8, 2003, Pages 869-878

  Waterhouse, Rikki N ^a  

^a New York State Psychiatric Institute ^*  (United States)

Author keywords

Glutamate; NMDA; PET; Phencyclidine; Radiotracer; SPECT

Indexed keywords

ANESTHETIC AGENT; ION CHANNEL; ISOFLURANE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHENCYCLIDINE; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; TRACER;

CONFERENCE PAPER; DRUG BINDING SITE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TARGETING; EXPERIMENTAL MODEL; HUMAN; IMAGE ANALYSIS; IMAGING SYSTEM; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LIGAND BINDING; MOLECULAR DYNAMICS; NONHUMAN; POSITRON EMISSION TOMOGRAPHY;

EID: 0346100526     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(03)00127-6     Document Type: Conference Paper

References (106)

1. Albers G.W., Clark W.M., Atkinson R.P., Madden K., Data J.L., Whitehouse M.J. Dose escalation study of the NMDA glycine-site antagonist licostinel in acute ischemic stroke. Stroke. 30:(3):1999;508-513.
2. Ametamey S.M., Bruehlmeier M., Kneifel S., Kokic M., Honer M., Arigoni M., Buck A., Burger C., Samnick S., Quack G., Schubiger P.A. PET studies of 18F-memantine in healthy volunteers. Nucl Med Biol. 29:(2):2002;227-231.
3. Ametamey S.M., Samnick S., Leenders K.L., Vontobel P., Quack G., Parsons C.G., Schubiger P.A. Fluorine-18 radiolabelling, biodistribution studies and preliminary PET evaluation of a new memantine derivative for imaging the NMDA receptor. J Recept Signal Transduct Res. 19:(1-4):1999;129-141.
4. Areosa SA, Sherriff F. Memantine for dementia. Cochrane Database of Systematic Reviews (Online: Update Software) 2003(1);CD003154:
5. Arvidsson A., Kokaia Z., Lindvall O. N-methyl-D-aspartate receptor-mediated increase of neurogenesis in adult rat dentate gyrus following stroke. Eur J Neurosci. 14:(1):2001;10-18.
6. Ball E.F., Shaw P.J., Ince P.G., Johnson M. The distribution of excitatory amino acid receptors in the normal human midbrain and basal ganglia with implications for Parkinson's disease a quantitative autoradiographic study using [3H]MK-801, [3H]glycine, [3H]CNQX and [3H]kainate . Brain Res. 658:(1-2):1994;209-218.
7. Blanpied T.A., Boeckman F.A., Aizenman E., Johnson J.W. Trapping channel block of NMDA-activated responses by amantadine and memantine. J Neurophysiol. 77:(1):1997;309-323.
8. Blin J., Denis A., Yamaguchi T., Crouzel C., MacKenzie E.T., Baron J.C. PET studies of [18F]methyl-MK-801, a potential NMDA receptor complex radioligand. Neurosci Lett. 121:(1-2):1991;183-186.
9. Brown D.R., Wyper D.J., Owens J., Patterson J., Kelly R.C., Hunter R., McCulloch J. 123Iodo-MK-801 a spect agent for imaging the pattern and extent of glutamate (NMDA) receptor activation in Alzheimer's disease . J Psychiatr Res. 31:(6):1997;605-619.
10. Carroll R.C., Zukin R.S. NMDA-receptor trafficking and targeting implications for synaptic transmission and plasticity . Trends Neurosci. 25:(11):2002;571-577.
11. Chahal H., D'Souza S.W., Barson A.J., Slater P. Modulation by magnesium of N-methyl-D-aspartate receptors in developing human brain. Arch Dis Childhood (Fetal And Neonatal Edition). 78:(2):1998;F116-120.
12. Chen H.S., Lipton S.A. Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells uncompetitive antagonism . J Physiol. 499:(Pt 1):1997;27-46.
13. Christie J.M., Jane D.E., Monaghan D.T. Native N-methyl-D-aspartate receptors containing NR2A and NR2B subunits have pharmacologically distinct competitive antagonist binding sites. J Pharmacol Exp Thera. 292:(3):2000;1169-1174.
14. Currás M.C., Pallotta B.S. Single-channel evidence for glycine and NMDA requirement in NMDA receptor activation. Brain Res. 740:(1-2):1996;27-40.
15. Dannhardt G., Kohl B.K. The glycine site on the NMDA receptor structure-activity relationships and possible therapeutic applications . Curr Med Chem. 5:(4):1998;253-263.
16. Danysz W., Parsons C., Kornhuber J., Schmidt W., Quack G. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies. Neurosci Biobehav Rev. 21:(4):1997;455-468.
17. Deutsch S.I., Mastropaolo J., Schwartz B.L., Rosse R.B., Morihisa J.M. A glutamatergic hypothesis of schizophrenia. Rationale for pharmacotherapy with glycine. Clin Neuropharmacol. 12:(1):1989;1-13.
18. Difazio M.C., Hollingsworth Z., Young A.B., Penney J.B.J. Glutamate receptors in the substantia nigra of Parkinson's disease brains. Neurology. 42:(2):1992;402-406.
19. Dingledine R., Myers S.J., Nicholas R.A. Molecular biology of mammalian amino acid receptors. Faseb Journal. 4:(9):1990;2636-2645.
20. Dumont F., Sultana A., Waterhouse R.N. Synthesis and in vitro evaluation of N,N′-diphenyl and N-naphthyl-N′-phenylguanidines as N-methyl-D-aspartate receptor ion-channel ligands. Bioorg Med Chem Lett. 12:(12):2002;583-586.
21. Erlandsson K., Bressan R.A., Mulligan R.S., Gunn R.N., Cunningham V.J., Owens J., Wyper D., Ell P.J., Pilowsky L.S. Kinetic modelling of [(123)I]CNS 1261-a potential SPET tracer for the NMDA receptor. Nucl Med Biol. 30:(4):2003;441-454.
22. Ferrarese C., Guidotti A., Costa E., Miletich R.S., Rice K.C., de Costa B.R., Fulham M.J., Di Chiro G. In vivo study of NMDA-sensitive glutamate receptor by fluorothienylcyclohexylpiperidine [correction of fluorothienylcycloexylpiperidine], a possible ligand for positron emission tomography. Neuropharmacol. 30:(8):1991;899-905.
23. Gibson E.G., Burns D.H., Thorpe H.H., Eng W.S., Ransom R., Solomon H. In vivo binding and autoradiographic imaging of (+)-3-[125I]Iodo-MK-801 to the NMDA receptor-channel complex in rat brain. International Journal of Radiation Applications and Instrumentation. Part B. Nucl Med Biol. 19:(3):1992;319-326.
24. Harada H., Kelly P.J., Cole D.J., Drummond J.C., Patel P.M. Isoflurane reduces N-methyl-D-aspartate toxicity in vivo in the rat cerebral cortex. Anesth Analg. 89:(6):1999;1442-1447.
25. Hartvig P., Valtysson J., Antoni G., Westerberg G., Langstrom B., Ratti Moberg E., Oye I. Brain kinetics of (R)- and (S)-[N-methyl-11C]ketamine in the rhesus monkey studied by positron emission tomography (PET). Nucl Med Biol. 21:(7):1994;927-934.
26. Hartvig P., Valtysson J., Antoni G., Westerberg G., Langstrom B., Ratti-Moberg E., Oye I. Brain kinetics of (R)- and (S)-[N-methyl-11C]ketamine in the rhesus monkey studied by positron emission tomography (PET). Nucl Med Biol. 21:(7):1994;927-934.
27. Heresco-Levy U., Javitt D. The role of N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes. Eur Neuropsychopharmacol. 8:(2):1998;141-152.
28. Heresco-Levy U., Silipo G., Javitt D.C. Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia. Psychopharmacol Bull. 32:(4):1996;731-740.
29. Hollmann M.W., Liu H.T., Hoenemann C.W., Liu W.H., Durieux M.E. Modulation of NMDA receptor function by ketamine and magnesium. Part II interactions with volatile anesthetics . Anesth Analg. 92:(5):2001;1182-1191.
30. Hu L.Y., Guo J., Magar S.S., Fischer J.B., Burke-Howie K.J., Durant G.J. Synthesis and pharmacological evaluation of N-(2,5-disubstituted phenyl)-N′-(3-substituted phenyl)-N′-methylguanidines as N-methyl-D-aspartate receptor ion-channel blockers. J Med Chem. 40:(26):1997;4281-4289. [published erratum appears in J Med Chem 1998 Mar 12;41(6):1006].
31. Ishizaki K., Yoon D.M., Yoshida N., Yamazaki M., Arai K., Fujita T. Intrathecal administration of N-methyl-D-aspartate receptor antagonist reduces the minimum alveolar anaesthetic concentration of isoflurane in rats. Br J Anaesth. 75:(5):1995;636-638.
32. Ishizaki K., Yoshida N., Yoon D.M., Yoon M.H., Sudoh M., Fujita T. Intrathecally administered NMDA receptor antagonists reduce the MAC of isoflurane in rats. Can J Anaesth. 43:(7):1996;724-730.
33. Jang C., Park Y., Rockhold R.W., Ho I.K. Autoradiographic study of NMDA-displaceable [3H]glutamate and [3H]MK-801 binding during butorphanol withdrawal in the rat brain. Brain Res. 845:(2):1999;236-241.
34. Javitt D.C., Frusciante M. Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake implications for schizophrenia and substance abuse . Psychopharmacol. 129:(1):1997;96-98.
35. Javitt D.C., Zukin S.R. Biexponential kinetics of [3H]MK-801 binding evidence for access to closed and open N-methyl-D-aspartate receptor channels . Mol Pharmacol. 35:(4):1989;387-393.
36. Javitt D.C., Zukin S.R. Interaction of [3H]MK-801 with multiple states of the N-methyl-D-aspartate receptor complex of rat brain. Proc Natl Acad Sci U S A. 86:(2):1989;740-744.
37. Javitt D.C., Zylberman I., Zukin S.R., Heresco-Levy U., Lindenmayer J.P. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psych. 151:(8):1994;1234-1236.
38. Keana J.F., McBurney R.N., Scherz M.W., Fischer J.B., Hamilton P.N., Smith S.M., Server A.C., Finkbeiner S., Stevens C.F., Jahr C., et al. Synthesis and characterization of a series of diarylguanidines that are noncompetitive N-methyl-D-aspartate receptor antagonists with neuroprotective properties. Proc Natl Acad Sci U S A. 86:(14):1989;5631-5635.
39. Keita H., Henzel-Rouelle D., Dupont H., Desmonts J.M., Mantz J. Halothane and isoflurane increase spontaneous but reduce the N-methyl-D-aspartate-evoked dopamine release in rat striatal slices evidence for direct presynaptic effects . Anesthesiology. 91:(6):1999;1788-1797.
40. Kokic M, Honer M, Kessler LJ, Grauert M, Schubiger PA, Ametamey AM. Synthesis and in vitro and in vivo evaluation of [11C]methyl-BIII277CL for imaging the PCP-binding site of the NMDA receptor by pet. J Recept Signal Transduct Res 22(1-4):123-39.
41. Kornhuber J., Weller M., Schoppmeyer K., Riederer P. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Trans (Supplementum). 43:1994;91-104.
42. Krystal J.H., D'Souza D.C. D-serine and the therapeutic challenge posed by the N-methyl-D-aspartate antagonist model of schizophrenia [editorial; comment]. Biolog Psych. 44:(11):1998;1075-1076.
43. Krystal J.H., D'Souza D.C., Petrakis L.L., Belger A., Berman R.M., Charney D.S., Abi-Saab W., Madonick S. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harvard Rev Psych. 7:(3):1999;125-143.
44. Kumlien E., Hartvig P., Valind S., Oye I., Tedroff J., Langstrom B. NMDA-receptor activity visualized with (S)-[N-methyl-11C]ketamine and positron emission tomography in patients with medial temporal lobe epilepsy. Epilepsia. 40:(1):1999;30-37.
45. Kuroda Y., Strebel S., Rafferty C., Bullock R. Neuroprotective doses of N-methyl-D-aspartate receptor antagonists profoundly reduce the minimum alveolar anesthetic concentration (MAC) for isoflurane in rats. Anesth Analg. 77:(4):1993;795-800.
46. Lamdani-Itkin H., Kloog Y., Sokolovsky M. Modulation of glutamate-induced uncompetitive blocker binding to the NMDA receptor by temperature and by glycine. Biochemistry. 29:(16):1990;3987-3993.
47. Laurie D.J., Seeburg P.H. Ligand affinities at recombinant N-methyl-D-aspartate receptors depend on subunit composition. Eur J Pharmacol. 268:(3):1994;335-345.
48. Lees K.R. Cerestat and other NMDA antagonists in ischemic stroke. Neurology. 49:(5 Suppl 4):1997;S66-69.
49. Li H., Matsumoto K., Tohda M., Yamamoto M., Watanabe H. NMDA antagonists potentiate scopolamine-induced amnesic effect. Behav Brain Res. 83:(1-2):1997;225-228.
50. Luk K.C., Kennedy T.E., Sadikot A.F. Glutamate promotes proliferation of striatal neuronal progenitors by an NMDA receptor-mediated mechanism. J Neurosci (the Official Journal of the Society For Neuroscience). 23:(6):2003;2239-2250.
51. Lynch D.R., Anegawa N.J., Verdoorn T., Pritchett D.B. N-methyl-D-aspartate receptors different subunit requirements for binding of glutamate antagonists, glycine antagonists, and channel-blocking agents . Mol Pharmacol. 45:(3):1994;540-545.
52. Magnusson K.R. Differential effects of aging on binding sites of the activated NMDA receptor complex in mice. Mech Age Develop. 84:(3):1995;227-243.
53. Martin D.C., Plagenhoef M., Abraham J., Dennison R.L., Aronstam R.S. Volatile anesthetics and glutamate activation of N-methyl-D-aspartate receptors. Biochem Pharmacol. 49:(6):1995;809-817.
54. McCoy L., Richfield E.K. Washable endogenous substances and regional heterogeneity in agonist enhanced [3H]MK-801 binding in rat brain. Brain Res. 710:(1-2):1996;103-111.
55. McDonald J.W., Penney J.B., Johnston M.V., Young A.B. Characterization and regional distribution of strychnine-insensitive [3H]glycine binding sites in rat brain by quantitative receptor autoradiography. Neuroscience. 35:(3):1990;653-668.
56. McEwen BS. Sex, stress, and the hippocampus: allostasis, allostatic load, and the aging process. Neurobiol Aging 23(5):921-39.
57. McEwen B.S. Stress and hippocampal plasticity. Ann Rev Neurosci. 22:1999;105-122.
58. Mealing G.A., Lanthorn T.H., Murray C.L., Small D.L., Morley P. Differences in degree of trapping of low-affinity uncompetitive N-methyl-D-aspartic acid receptor antagonists with similar kinetics of block. J Pharmacol Exp Therap. 288:(1):1999;204-210.
59. Mealing G.A., Lanthorn T.H., Small D.L., Murray R.J., Mattes K.C., Comas T.M., Morley P. Structural modifications to an N-methyl-D-aspartate receptor antagonist result in large differences in trapping block. J Pharmacol Exp Therap. 297:(3):2001;906-914.
60. Meldrum B.S. Glutamate as a neurotransmitter in the brain review of physiology and pathology . J Nutr. 130:(4S Suppl):2000;1007S-1015S.
61. Michalak A., Butterworth R.F. Selective loss of binding sites for the glutamate receptor ligands [3H]kainate and (S)-[3H]5-fluorowillardiine in the brains of rats with acute liver failure. Hepatology. 25:(3):1997;631-635.
62. Miyoshi R., Kito S., Doudou N., Nomoto T. Influence of age on N-methyl-D-aspartate antagonist binding sites in the rat brain studied by in vitro autoradiography. Synapse. 8:(3):1991;212-217.
63. Murray F., Kennedy J., Hutson P.H., Elliot J., Huscroft I., Mohnen K., Russell M.G.N., Grimwood S. Modulation of [3H]MK-801 binding to NMDA receptors in vivo and in vitro. Eur J Parmacol. 398:2000;263-270.
64. Nacher J., Rosell D.R., Alonso-Llosa G., McEwen M.S. NMDA receptor antagonist treatment induces a long-lasting increase in the number of proliferating cells, PSA-NCAM-immunoreactive granule neurons and radial glia in the adult rat dentate gyrus. Eur J Neurosci. 13:(3):2001;512-520.
65. Nakanishi S., Nakajima Y., Masu M., Ueda Y., Nakahara K., Watanabe D., Yamaguchi S., Kawabata S., Okada M. Glutamate receptors brain function and signal transduction . Brain Res Brain Res Reviews. 26:(2-3):1998;230-235.
66. Newcomer J., Farber N., Jevtovic-Todorovic V., Selke G., Melson A., Hershey T., Craft S., Olney J. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacol. 20:(2):1999;106-118.
67. Nishikawa K., MacIver M.B. Excitatory synaptic transmission mediated by NMDA receptors is more sensitive to isoflurane than are non-NMDA receptor-mediated responses. Anesthesiology. 92:(1):2000;228-236.
68. Olney J.W., Labruyere J., Wang G., Wozniak D.F., Price M.T., Sesma M.A. NMDA antagonist neurotoxicity mechanism and prevention . Science. 254:(5037):1991;1515-1518.
69. Orita K., Sasaki S., Maeda M., Hashimoto A., Nishikawa T., Yugami T., Umezu K. Synthesis and evaluation of 1-(1-[5-(2′-[18F]fluoroethyl)-2- thienyl]-cyclohexyl)piperidine as a potential in vivo radioligand for the NMDA receptor-channel complex. Nucl Med Biol. 20:(7):1993;865-873.
70. Ossowska K., Lorenc-Koci E., Konieczny J., Wolfarth S. The role of striatal glutamate receptors in models of Parkinson's disease. Amino Acids. 14:(1-3):1998;11-15.
71. Otoya R.E., Seltzer A.M., Donoso A.O. Decrease of (+)-3-[125I]MK-801 binding to NMDA brain receptors revealed at puberty in rats treated neonatally with monosodium glutamate. Brain Res Dev Brain Res. 95:(2):1996;149-156.
72. Owens J., Tebbutt A.A., McGregor A.L., Kodama K., Magar S.S., Perlman M.E., Robins D.J., Durant G.J., McCulloch J. Synthesis and binding characteristics of N-(1-naphthyl)-N′-(3-[(125)I]-iodophenyl)-N′- methylguanidine ([(125)I]-CNS 1261) a potential SPECT agent for imaging NMDA receptor activation . Nucl Med Biol. 27:(6):2000;557-564.
73. Owens J., Wyper D.J., Patterson J., Brown D.R., Elliott A.T., Teasdale G.M., McCulloch J. First SPET images of glutamate (NMDA) receptor activation in vivo in cerebral ischaemia. Nucl Med Comm. 18:(2):1997;149-158.
74. Parsons C.G., Danysz W., Hessenlink M., Hartmann S., Lorenz B., Wollenburg C., Quack G. Modulation of NMDA receptors by glycine-introduction to some basic aspects and recent developments. Amino Acids. 14:1998;207-216.
75. Peeters B.W., Vanderheyden P.M. In vitro and in vivo characterization of the NMDA receptor-linked strychnine-insensitive glycine site. Epilepsy Res. 12:(2):1992;157-162.
76. Priestley T., Kemp J.A. Kinetic study of the interactions between the glutamate and glycine recognition sites on the N-methyl-D-aspartic acid receptor complex. Mol Pharmacol. 46:(6):1994;1191-1196.
77. Ransom R.W., Eng W.S., Burns H.D., Gibson R.E., Solomon H.F. (+)-3-[123I]Iodo-MK-801 synthesis and characterization of binding to the N-methyl-D-aspartate receptor complex . Life Sciences. 46:(15):1990;1103-1110.
78. Reddy N.L., Hu L.Y., Cotter R.E., Fischer J.B., Wong W.J., McBurney R.N., Weber E., Holmes D.L., Wong S.T., Prasad R., et al. Synthesis and structure-activity studies of N,N′-diarylguanidine derivatives. N-(1-naphthyl)-N′-(3-ethylphenyl)-N′-methylguanidine a new, selective noncompetitive NMDA receptor antagonist . J Med Chem. 37:(2):1994;260-267.
79. Reid I., Stewart C. Seizures, memory and synaptic plasticity. Seizure. 6:(5):1997;351-359.
80. Reynolds I.J., Miller R.J. Allosteric modulation of N-methyl-D-aspartate receptors. Adv Pharmacol. 21:1990;101-126.
81. Reynolds I.J., Rothermund K., Rajdev S., Fauq A.H., Kozikowski A.P. [125I]thienylphencyclidine, a novel ligand for the NMDA receptor. Eur J Pharmacol. 226:(1):1992;53-58.
82. Roche K.W., Standley S., McCallum J., Dune-Ly C., Ehlers M.D., Wenthold R.J. Molecular determinants of NMDA receptor internalization. Nature Neuroscience. 4:(8):2001;794-802.
83. Rogawski M.A. Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents-toward an understanding of their favorable tolerability. Amino Acids. 19:(1):2000;133-149.
84. Rörig B., Grantyn R. Ligand- and voltage-gated ion channels are expressed by embryonic mouse retinal neurones. Neuroreport. 5:(10):1994;1197- 1200.
85. Sahai S. Glutamate in the mammalian CNS. Eur Arch Psychiatry Clin Neurosci. 240:(2):1990;121-133.
86. Sakurai S.Y., Penney J.B., Young A.B. Regionally distinct N-methyl-D-aspartate receptors distinguished by quantitative autoradiography of [3H]MK-801 binding in rat brain. J Neurochem. 60:(4):1993;1344-1353.
87. Samnick S., Ametamey S., Leenders K.L., Vontobel P., Quack G., Parsons C.G., Neu H., Schubiger P.A. Electrophysiological study, biodistribution in mice, and preliminary PET evaluation in a rhesus monkey of 1-amino-3-[18F] fluoromethyl-5-methyl-adamantane (18F-MEM) a potential radioligand for mapping the NMDA-receptor complex . Nucl Med Biol. 25:(4):1998;323-330.
88. Scatton B. The NMDA receptor complex. Fundam Clin Pharmacol. 7:(8):1993;389-400.
89. Schoepfer R., Monyer H., Sommer B., Wisden W., Sprengel R., Kuner T., Lomeli H., Herb A., Kohler M., Burnashev N. Molecular biology of glutamate receptors. Prog Neurobiol. 42:(2):1994;353-357.
90. Shiue C.Y., Vallabhahosula S., Wolf A.P., Dewey S.L., Fowler J.S., Schlyer D.J., Arnett C.D., Zhou Y.G. Carbon-11 labelled ketamine-synthesis, distribution in mice and PET studies in baboons. Nucl Med Biol. 24:(2):1997;145-150.
91. Sihver S., Sihver W., Andersson Y., Murata T., Bergstrom M., Onoe H., Matsumura K., Tsukada H., Oreland L., Langstrom B., Watanabe Y. In vitro and in vivo characterization of (+)-3-[11C]cyano-dizocilpine. J Neural Transm. 105:(2-3):1998;117-131.
92. Smythies J.R. Biological markers for the schizophrenic and atypical psychoses. J Nerv Ment Dis. 170:(12):1982;732-736.
93. Sobolevsky AI, Yelshansky MV. The trapping block of NMDA receptor channels in acutely isolated rat hippocampal neurones. 2000;526:Pt 3:493-506.
94. Sun A., Cheng J. Novel targets for therapeutic intervention against ischemic brain injury. Clin Neuropharmacol. 22:(3):1999;164-171.
95. Suzuki Y., Takagi Y., Nakamura R., Hashimoto K., Umemura K. Ability of NMDA and non-NMDA receptor antagonists to inhibit cerebral ischemic damage in aged rats. Brain Res. 964:(1):2003;116-120.
96. Thomas R.J. Excitatory amino acids in health and disease. J Am Geriatr Soc. 43:(11):1995;1279-1289.
97. Turski L. [The N-methyl-D-aspartate receptor complex. Various sites of regulation and clinical consequences]. Arzneimittel-Forschung. 40:(5):1990;511-514.
98. Villmann C., Strutz N., Morth T., Hollmann M. Investigation by ion channel domain transplantation of rat glutamate receptor subunits, orphan receptors and a putative NMDA receptor subunit. Eur J Neurosci. 11:(5):1999;1765-1778.
99. Waterhouse RN. Determination of lipophilicity and its use as a predictor of radiotracer blood-brain barrier penetration and outcome measuRes molecular imaging and biology, 2003. (in press).
100. Waterhouse R.N., Dumont F., Sultana A., Simpson N., Laruelle M. Synthesis of [11C]N-(2-chloro-5-thiomethylphenyl)-N′-(3-methoxyphenyl)- N′-methylguanidine ([11C]GMOM) a candidate PET tracer for imaging the PCP site of the NMDA ion channel . J Labelled Compds Radiopharm. 45:2002;955-964.
101. Waterhouse R.N., Dumont F., Sultana A., Slifstein M., Sudo Y., Simpson N., Laruelle M. [11C]N-(2-Chloro-5-Thiomethylphenyl)-N′-(3-methoxyphenyl)- N′-methyl-guanidine ([11C]GMOM) as a potential PET radiotracer for the PCP/NMDA receptor Synthesis and evaluation in rats and baboons . Neuroimage. 16:(3):2002;S24.
102. Waterhouse RN, Slifstein M, Dumont F, Sultana A, Balter A, Sudo Y, Laruelle M. In vivo evaluation of [11C]N-(2-chloro-5-thiomethylphenyl)-N′- (3-methoxyphenyl)-N′-methylguanidine ([11C]GMOM) as a potential PET radiotracer for the NMDA/PCP receptor. Nucl Med Biol 2003. (in press).
103. Yamakura T., Shimoji K. Subunit- and site-specific pharmacology of the NMDA receptor channel. Prog Neurobiol. 59:(3):1999;279-298.
104. Yeh G.C., Bonhaus D.W., Nadler J.V., McNamara J.O. N-methyl-D-aspartate receptor plasticity in kindling quantitative and qualitative alterations in the N-methyl-D-aspartate receptor-channel complex . Proc Natl Acad Sci U S A. 86:(20):1989;8157-8160.
105. Yoneda Y., Ogita K., Enomoto R., Kojima S., Shuto M., Shirahata A., Samejima K. Search for novel ligands selective at a polyamine recognition domain on the N-methyl-D-aspartate receptor complex using membrane binding techniques. Brain Res. 679:(1):1995;15-24.
106. Ziff E.B. Recent excitement in the ionotropic glutamate receptor field. Ann NY Acad Sci. 868:1999;465-473.